British pharma major AstraZeneca (LSE: AZN) has presented new data from the INFORM and COVIDRIVE real-world studies at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID).
The results show the significant burden of COVID-19 on immunocompromised patients, compared to the general population.
Data from INFORM show that, despite receiving at least four vaccinations, many such individuals remain poorly protected against the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze